TEVA UK HOLDCO 3 LIMITED
Get an alert when TEVA UK HOLDCO 3 LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-09-30 (in 4mo)
Last made up 2025-09-16
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£4B
USD 5,607,652,000
+284.4% vs 2023
Employees
0
Average over period
Profit before tax
£3B
USD 4,048,486,000
+302.4% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | — | — | |
| Profit before tax | -£1,495,285,939 | £3,026,452,867 | |
| Net profit | -£1,495,285,939 | £3,026,452,867 | |
| Cash | — | — | |
| Total assets less current liabilities | £1,090,419,377 | £4,831,978,770 | |
| Net assets | — | £4,192,010,167 | |
| Equity | — | £4,192,010,167 | |
| Average employees | 0 | 0 | |
| Wages | — | — | |
| Directors' remuneration | — | — |
Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
—
Not reported
-
Employees
—
Not reported
-
Profit before tax
+302.4%
-£1,495,285,939 £3,026,452,867
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Gearing (liabilities / total assets) | — | 24.4% | |
| Current ratio | 2.62x | 1.89x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors consider that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Group structure
- TEVA UK HOLDCO 3 LIMITED · parent
- Orvet UK 100%
- Teva Holdco US, Inc. 100%
- Anda Holdco Corp. 100%
- Anda Marketing, Inc. 100%
- Anda Pharmaceuticals, Inc. 100%
- Anda, Inc. 100%
- Anda Puerto Rico Inc. 100%
- Teva API, Inc. 100%
- Teva Digital Health, Inc. 100%
- Teva Pharmaceuticals USA, Inc. 100%
- Actavis Holdco US, Inc. 100%
- Actavis Laboratories UT, Inc. 100%
- Actavis Puerto Rico Holdings Inc. 100%
- Coventry Acquisition, LLC 100%
- Actavis Pharma, Inc. 100%
- Actavis Pharmaceuticals NJ, Inc. 100%
- Watson Laboratories, Inc [Connecticut] 100%
- Watson Pharma Private Limited 100%
- Andrx LLC 100%
- Actavis Laboratories FL, Inc. 100%
- Watson Management Corporation 100%
- Watson Therapeutics, Inc. 100%
- Circa Pharmaceuticals West, Inc. 100%
- Royce Research and Development Limited Partnership I 100%
- Watson Laboratories, Inc. [Nevada] 100%
- Actavis US Holding LLC 100%
- Actavis LLC 100%
- Actavis Elizabeth LLC 100%
- Actavis Kadian LLC 100%
- Actavis Mid Atlantic LLC 100%
- Actavis South Atlantic LLC 100%
- Actavis Totowa LLC 100%
- Cobalt Laboratories LLC 100%
- Watson Laboratories, LLC 100%
- Watson Manufacturing Services, Inc. 100%
- Watson Pharmaceuticals (Asia) Limited 100%
- Changzhou Siyao Pharmaceuticals Co., Ltd. 25%
- Watson Pharmaceuticals (China) Limited 100%
- Med All Enterprise Consulting (Shanghai) Co., Limited 100%
- WP Holdings, Ltd. 100%
- Watson Pharmaceuticals International, Limited 100%
- ANTARES PHARMA INC. 1%
- Auspex Pharmaceuticals LLC 100%
- Barr Pharmaceuticals, LLC 100%
- Barr Laboratories LLC 100%
- Barr International Services, Inc. 100%
- PLIVA, Inc. 100%
- Odyssey Pharmaceuticals, Inc. 100%
- Teva Women's Health, LLC 100%
- Teva Sales and Marketing, Inc. 100%
- Cupric Holding Co. LLC 100%
- Cephalon, LLC 100%
- Anesta LLC 100%
- Cephalon Development Corporation 100%
- Cephalon Clinical Partners, LP 100%
- CIMA Labs, Inc. 100%
- East End Insurance, Ltd. 100%
- Gecko Health Innovations, Inc. 100%
- IVAX LLC 100%
- IVAX Pharmaceuticals Mexico, S.A. de C.V. 100%
- IVAX (Bermuda) Ltd. 100%
- IVAX Argentina S.A. 100%
- IVAX Far East, Inc. 100%
- China National Pharmaceutical Logistics Corp. LTD 10%
- IVAX Holdings C.I. 100%
- Laboratorio Chile, S.A. 100%
- LBC International Corp. 100%
- Pharmatrade S.A. 100%
- Teva Pharmaceuticals Colombia S A S 100%
- TEVA INVERSIONES Y EXPORTACIONES SpA 100%
- IVAX Pharmaceuticals, LLC 100%
- Doral Manufacturing, Inc. 100%
- Goldline Laboratories, Inc. 100%
- IVAX Pharmaceuticals NV, LLC 100%
- IVAX Pharmaceuticals Caribe, Inc. 100%
- IVAX Specialty Chemicals Sub, LLC 100%
- Maancirkel Holding B.V. 100%
- Inmobiliaria Lemery, S.A. de C.V. 100%
- Patient Services and Solutions, Inc. 100%
- TAPI Puerto Rico, Inc. 100%
- Teva Branded Pharmaceutical Products R&D LLC 100%
- Teva Neuroscience, Inc. 100%
- Teva Pharmaceuticals Panama, S.A. 100%
- Teva Respiratory, LLC 100%
- IVAX Laboratories Puerto Rico, Inc. 100%
- TEVA Uruguay S.A. 100%
- Labrys Biologics, Inc. 100%
- MicroDose Therapeutx, Inc. 100%
- Sicor Inc. 100%
- Rakepoll Holding B.V. 100%
- Lemery S.A. de C.V. 100%
- Sicor de México S.A. de C.V. 100%
- TEVA Pharmaceuticals Mexico S.A. de C.V. 100%
- UAB Teva Baltics 100%
- Teva Parenteral Medicines, Inc. 100%
- Teva Biopharmaceuticals USA, Inc. 100%
- Teva Pharmaceutical Finance Company, LLC 100%
- Teva Pharmaceutical Finance IV, LLC 100%
- Teva Pharmaceutical Finance Netherlands III B.V. 100%
- Teva Pharmaceutical Finance V, LLC 100%
- Teva Pharmaceutical Finance VI, LLC 100%
- Teton Pharmaceuticals, LLC 100%
- GeminX Pharmaceuticals Canada, Inc. 100%
- Corporacion Medco CA 100%
- Schein Pharmaceuticals Bermuda Limited 100%
- Representaciones E Investigaciones Medicas SA
- Immobiliaria Leyfe, SA de C.V.
- Inter Lab Pharmaceutica, SA de C.V.
- Watson Laboratories S. de R.L. de C.V. 50%
- New Caribe CFC 100%
- Teva API Services Mexico S de RL de C.V. 50%
Significant events
- “During March 2024, a loan receivable from a fellow group company of USD 900,000,000 with a maturity date of 24 March 2024 was extended to 24 March 2034, and loan payables to fellow group companies of USD 900,000,000 with a maturity date of 24 March 2024 were also extended to 24 March 2034.”
- “In June 2024, a series of cash transactions were undertaken to reduce the intercompany indebtedness of a number of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 3 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva UK Holdco 2 Limited, 1,101,893,094 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 1,101,893,094.26.”
- “In August 2024, a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 3 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva UK Holdco 2 Limited, 457,273,600 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 457,273,600.”
- “In December 2024 the company entered into a share exchange agreement with its ultimate parent company, Teva Pharmaceutical Industries Ltd and this had the effect on Teva UK Holdco 3 Limited as described below: Under the share exchange agreement, the company allotted one ordinary share of USD 1.00 credited as fully paid to Teva Pharmaceutical Industries Ltd, in exchange for a USD 1.00 on-demand interest-free receivable and one ordinary share of USD 1.00 in the capital of the company's direct subsidiary, Orvet UK.”
- “At the balance sheet date, the directors undertook an exercise to estimate the recoverable value of the company's fixed asset investments, which resulted in a reversal of impairment of USD 4,048,486,000 during the year (2023: impairment of USD 2,000,244,000).”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| COOPER, Dean Michael | Director | 2019-09-17 | Sep 1972 | British |
| KATZ, Yaron Aizik, Mr | Director | 2022-05-07 | Dec 1968 | American |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HERMAN, Doron | Director | 2019-09-17 | 2022-05-07 |
| INNES, Kim | Director | 2019-09-17 | 2020-04-29 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Uk Holdco 1 Limited | Corporate entity | Shares 25–50%, Voting 25–50% | 2020-05-06 | Active |
| Teva Uk Holdco 2 Limited | Corporate entity | Shares 50–75%, Voting 50–75% | 2019-10-07 | Active |
| Orvet Uk | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-09-17 | Ceased 2019-10-07 |
Filing timeline
Last 20 of 39 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-20 | RP01SH01 | miscellaneous | Legacy | |
| 2025-10-06 | AA | accounts | Accounts with accounts type full | |
| 2025-09-29 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-08-14 | SH01 | capital | Capital allotment shares | |
| 2025-02-17 | SH01 | capital | Capital allotment shares | |
| 2025-01-30 | SH01 | capital | Capital allotment shares | |
| 2024-12-12 | RP04CS01 | confirmation-statement | Second filing of confirmation statement with made up date | |
| 2024-12-10 | SH01 | capital | Capital allotment shares | |
| 2024-10-21 | CS01 | confirmation-statement | Confirmation statement | |
| 2024-10-09 | AA | accounts | Accounts with accounts type full | |
| 2024-06-25 | SH01 | capital | Capital allotment shares | |
| 2023-12-14 | SH01 | capital | Capital allotment shares | |
| 2023-10-03 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-08-15 | AA | accounts | Accounts with accounts type full | |
| 2023-01-03 | AA | accounts | Accounts with accounts type full | |
| 2022-09-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-06-22 | SH01 | capital | Capital allotment shares | |
| 2022-05-11 | TM01 | officers | Termination director company with name termination date | |
| 2022-05-09 | AP01 | officers | Appoint person director company with name date | |
| 2021-11-12 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 5
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.